SEC Filing Summary: Cara Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. on February 2, 2024, reporting an event that occurred on February 1, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol CARA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance matter regarding the company's stock listing status.
Material Changes and Events
- Nasdaq Non-Compliance Notice: On February 1, 2024, the Company received notice from Nasdaq that it failed to comply with Listing Rule 5450(a)(1).
- Reason for Non-Compliance: The minimum bid price of the Company's common stock remained below $1.00 per share for 30 consecutive business days.
- Immediate Effect: The notification has no immediate effect on the listing or trading of the Company's common stock.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days (until July 30, 2024) to regain compliance.
- Requirements to Regain Compliance: The minimum bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days during the grace period.
- Alternative Path: If compliance is not met by July 30, 2024, the Company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market, subject to meeting other listing standards (excluding the bid price requirement).
- Risk of Delisting: Failure to regain compliance during the applicable periods could result in delisting.
- Management Stance: The Company intends to actively monitor the bid price and consider available options to regain compliance, though there is no assurance of success.
Key Facts for Investor Verification
- Verify the current trading price of CARA stock to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor for any announcements regarding a reverse stock split or other corporate actions intended to address the bid price deficiency.
- Check for any subsequent filings regarding the Company's intent to transfer to The Nasdaq Capital Market if the initial grace period expires without compliance.
- Review the Company's cash position in other filings (e.g., 10-K or 10-Q) to understand its ability to fund operations while addressing listing issues.